ArticleFrontiers in medicine2025
Serum concentrations of Krebs von den Lungen-6 as prognostic biomarker in patients with silicosis.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of Serum Prolidase as a Biomarker and the Effects of Nintedanib in an Experimental Rat Model of Silicosis.Journal of clinical medicine · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: KL-6, a pneumocyte derived biomarker, is increased in patients with interstitial lung diseases (ILDs). We aimed to investigate the role of serum KL-6 as a diagnostic and prognostic biomarker in silica-exposed workers. Material and method: We studied 108 silica-exposed subjects and 25 healthy controls. Chest radiography (CXR), pulmonary function tests, inflammatory markers were collected. Progressive massive fibrosis (PMF) was defined according to the ILO classification. KL-6 was measured in serum by fully automated CLEIA at first presentation at our institution, intended as baseline visit, with a time point from the initial exposure variable for each patient. Results: PMF was present in 23 subjects. Serum KL-6 levels were significantly higher in subjects with PMF than in controls, exposed workers or simple silicosis ( Conclusion: Serum KL-6 appears to be a promising biomarker for the occurrence and progression of PMF in silica-exposed workers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.